A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
- 1 November 1998
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (11), 1079-1089
- https://doi.org/10.1046/j.1365-2036.1998.00418.x
Abstract
Rabeprazole (LY307640, E3810) is a new, potent, proton pump inhibitor. A single daily 20 mg dose significantly decreases 24-h intragastric acidity. There are no data currently available directly comparing the effect of rabeprazole on 24-h acidity with established proton pump inhibitors. To compare the effects of rabeprazole 20 mg o.m. and omeprazole 20 mg o.m. on 24-h intragastric acidity and plasma gastrin concentration in a randomized, double-blind, placebo-controlled trial, in healthy H. pylori-negative subjects. Twenty-four healthy male volunteers, negative for H. pylori infection by serology and 13C-urea breath test, were studied on the 1st and 8th day of dosing with either placebo, rabeprazole 20 mg or omeprazole 20 mg, once each morning, in a crossover fashion. On days 1 and 8, hourly intragastric acidity was measured by gastric aspiration for 24 h from 08.00 hours. On day 8, plasma gastrin concentrations were also measured hourly from 08.00 to 24.00 hours, then every 2 h thereafter. A single dose of both rabeprazole and omeprazole significantly decreased 24-h intragastric acidity compared with placebo. The 24-h acidity on day 1 was significantly decreased for rabeprazole compared with omeprazole (331 vs. 640 mmol.h/L, P < 0.001), resulting in a significantly higher median 24-h intragastric pH and longer times at which intragastric pH was > 3 and > 4. On day 8 of dosing, the decrease in 24-h intragastric acidity was greater with rabeprazole than with omeprazole, but the difference was not statistically significant (160 vs. 218 mmol.h/L, P = 0.1). However, 24-h plasma gastrin concentration (1687 vs. 1085 pmol.h/L. P < 0.01) and percentage time that intragastric pH was > 3 (69 vs. 59%, P = 0.008) and > 4 (60 vs. 51%, P = 0.03) were significantly greater. Rabeprazole 20 mg once daily has a significantly faster onset of antisecretory activity than omeprazole 20 mg once daily. After 8 days the differences in intragastric pH > 3 and > 4 holding times persisted, but there was no significant difference in 24-h acidity.Keywords
This publication has 32 references indexed in Scilit:
- Acid‐inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori‐negative healthy subjectsAlimentary Pharmacology & Therapeutics, 1998
- Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))Digestive Diseases and Sciences, 1998
- Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus.Gut, 1997
- Atrophic Gastritis andHelicobacter pyloriInfection in Patients with Reflux Esophagitis Treated with Omeprazole or FundoplicationNew England Journal of Medicine, 1996
- Mechanism of Inhibition of H+, K+-ATPase by Sodium 2-((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-lH- benzimidazole (E3810).CHEMICAL & PHARMACEUTICAL BULLETIN, 1996
- The proton pump inhibitor, E3810, binds to the N-terminal half of the α-subunit of gastric H+,K+-ATPaseBiochemical Pharmacology, 1995
- Effects of the Proton Pump Inhibitor, E3810, on Gastric Secretion and Gastric and Duodenal Ulcers or Erosions in RatsClinical Drug Investigation, 1991
- Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathioneBiochemical Pharmacology, 1991
- The Pharmacokinetics of Single and Repeated Once-Daily Doses of 10, 20 and 40mg Omeprazole as Enteric-Coated GranulesClinical Drug Investigation, 1991
- Is there an optimal degree of acid suppression for healing of duodenal ulcers?Gastroenterology, 1990